Related Experiment Video
Updated: Sep 21, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma
Nirosha D Perera1, Aaron S Mansfield2
1Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Purpose Of Review:
For patients with malignant pleural mesothelioma, prognosis is poor with extremely low 5-year survival rates and limited therapeutic options. Here, we review the current treatment landscape for mesothelioma and highlight promising future therapeutic directions.
Recent Findings:
Evolving frontline therapeutic options for mesothelioma include VEGF inhibition in combination with chemotherapy and dual immune checkpoint inhibition, with synergisms between the therapies and response prediction via biomarkers also being explored. Evolving experimental treatments for mesothelioma include PARP and ALK inhibitors, dendritic and CAR T-cell therapies, anti-mesothelin vaccines, and oncolytic viral therapies, representing timely advances in the field. The therapeutic landscape for malignant pleural mesothelioma is evolving and preferred treatment in the frontline and later settings will likely evolve with it. However, this does not preclude the evidence for including multi-modal therapies spanning angiogenesis and immune checkpoint inhibitors, and biomarker utilization, in current clinical trials and management.
Insights
Malignant pleural mesothelioma has a poor prognosis, but new treatments are emerging. Future therapies combine VEGF inhibition, immune checkpoint inhibitors, and biomarker strategies for improved outcomes.
Area of Science:
- Oncology
- Thoracic Surgery
- Immunotherapy
Background:
- Malignant pleural mesothelioma has a dismal prognosis with limited treatment options.
- Current 5-year survival rates are extremely low, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the current treatment landscape for malignant pleural mesothelioma.
- To highlight promising future therapeutic directions and emerging treatments.
Main Methods:
- Review of evolving frontline therapies including VEGF inhibition and dual immune checkpoint inhibition.
- Exploration of experimental treatments such as PARP and ALK inhibitors, cell-based therapies, vaccines, and oncolytic viruses.
Main Results:
- Frontline options are evolving with combinations of chemotherapy and VEGF inhibition, and dual immune checkpoint inhibition.
- Experimental treatments show promise, including targeted therapies, immunotherapies, and novel vaccine and viral strategies.
- Biomarker utilization is crucial for predicting treatment response.
Conclusions:
- The therapeutic landscape for malignant pleural mesothelioma is rapidly evolving.
- Multi-modal therapies combining angiogenesis and immune checkpoint inhibitors, alongside biomarker utilization, are key for current and future clinical management.
More Related Videos
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...